Gilead Sciences Inc (NAS:GILD)
$ 67.9 0.18 (0.27%) Market Cap: 84.59 Bil Enterprise Value: 104.85 Bil PE Ratio: 188.61 PB Ratio: 4.83 GF Score: 74/100

Gilead Sciences Inc at Sanford C Bernstein Strategic Decisions Conference (Virtual) Transcript

Jun 02, 2021 / 08:30PM GMT
Release Date Price: $66.03 (+1.09%)
Aaron Gal
Sanford C. Bernstein & Co., LLC., Research Division - Senior Research Analyst

Hi, everybody, and thank you for joining us today. Our last discussion for today is with the Gilead team. We've got Merdad and Johanna here to talk to us, representing the R&D and commercial sides of Gilead. So thank you both for making the time for us today. I really, really appreciate it.

As Gilead is kind of a company with like an HIV -- largely HIV-based and an oncology product on top of it, we thought about dividing the discussion to just that. We'll first talk a little bit of oncology, which has a few of the near-term catalysts, and then go over to HIV and discuss both the R&D and commercial sides there.

Questions & Answers

Aaron Gal
Sanford C. Bernstein & Co., LLC., Research Division - Senior Research Analyst

So Merdad, we'll start with you. You came to Gilead from Roche. And in your -- and you've got a long career in the industry. What is your take, what does Gilead have that is special on the R&D side? What do they have that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot